Which medication should be clarified before administration to a patient going for dialysis?

Lisinopril, which is an ACE inhibitor, is particularly important to clarify before administering to a patient going for dialysis due to its effects on renal function and the potential risks of hyperkalemia. In patients with compromised kidney function, such as those undergoing dialysis, the renal excretion of potassium is significantly reduced. This can lead to elevated potassium levels in the blood if medications that contribute to potassium retention, like lisinopril, are administered without proper consideration.

In addition, ACE inhibitors can play a complex role in patients with renal impairment. They are sometimes used to manage hypertension or heart failure, but in the setting of dialysis, monitoring of renal function and electrolytes is crucial. The clinician must ensure that administering lisinopril is appropriate given the patient's overall clinical picture, especially regarding potassium levels and existing dialysis prescriptions.

The other medications listed generally pose less immediate concern in the context of dialysis. While atorvastatin may require monitoring of liver function, ondansetron is usually safe for use in most patients undergoing dialysis. Famotidine, a histamine H2-receptor antagonist, is also often safe and effective for the management of gastric issues in dialysis patients. However, lisinopril's specific interactions with renal function and potassium balance necess